Clinical Trial

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-10-07; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2026-02-10
Trial Details
NCT Number NCT07213973
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa (HS)
Enrollment 40 participants
Start Date 2026-02-02
Primary Completion 2028-03-25 (estimated)
Study Completion 2028-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-06